Compare Ferrari NV (RACE) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Ferrari (RACE) trades at $386.39, down 0.03% on the day, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue and net income have grown steadily from 2022 to 2025, supported by robust profitability margins. Recent news highlights a share buyback program and strategic partnerships, while institutional investors show increased interest.

The outlook remains positive due to strong financial performance and analyst consensus, with a price target of $462.75 implying ~20% upside. Risks include high valuation multiples, economic sensitivity, and execution challenges in electric vehicle initiatives. The stock offers growth potential but requires monitoring of competitive and macroeconomic pressures.

Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.

The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.